Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.

Summary What is known and Objective: BILR 355 is a second generation non-nucleoside reverse transcriptase inhibitor. It has shown promising in vitro anti-HIV-1 activities and favourable human pharmacokinetic properties after co-administration with ritonavir (RTV). Lamivudine (3TC) is a nucleoside re...

Descripción completa

Detalles Bibliográficos

Publicado en:	Journal of Clinical Pharmacy & Therapeutics Vol. 37; no. 1; pp. 81 - 89
Autores principales:	Huang, F., Allen, L., Huang, D. B., Moy, F., Vinisko, R., Nguyen, T., Rowland, L., MacGregor, T. R., Castles, M. A., Robinson, P.
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Wiley-Blackwell Feb2012
Acceso en línea:	Ver este registro en EBSCOhost